APA (7th ed.) Citation

Vlasta Oršić Frič, Vladimir Borzan, Ines Šahinović, Andrej Borzan, & Sven Kurbel. (2023). Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience. MDPI AG.

Chicago Style (17th ed.) Citation

Vlasta Oršić Frič, Vladimir Borzan, Ines Šahinović, Andrej Borzan, and Sven Kurbel. Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety After the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience. MDPI AG, 2023.

MLA (9th ed.) Citation

Vlasta Oršić Frič, et al. Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety After the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience. MDPI AG, 2023.